Endo Days Spring 2023 Conference

For CME:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Washington State Medical Association (WSMA) and the Endocrine Days Educational Institute. The WSMA is accredited by the ACCME to provide continuing medical education for physicians.   

The WSMA designates this Live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

This activity meets the criteria for up to 5.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

For MOC:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Planners: The following planners have indicated (a) relevant financial relationship(s) with an ACCME-defined ineligible company:

Savitha Subramanian, Abbott Diabetes Care, advisory board member. Kristina Utzschneider, Clinical Care Options, speaker; Nevro Corporation, consultant.

All relevant financial relationships have been mitigated. All others in control of content have indicated no relevant financial relationship with an ACCME-defined ineligible company. All clinical content presented will be evidence-based and unbiased.

​

Faculty: The following faculty have indicated (a) relevant financial relationship(s) with an ACCME-defined ineligible company:

Richard Auchus, Novartis Pharmaceuticals, investigator, consultant; Neurocrine Biosciences, investigator, consultant; Spruce Biosciences, investigator; Corcept Therapeutics, investigator, consultant; Diurnal, LTD, investigator; Sparrow Pharmaceuticals, investigator; Xeris Pharmaceuticals, consultant; Crinetics Pharmaceuticals, consultant; Adrenas Therapeutics, consultant; PhaseBio Pharmaceuticals, consultant; Novo Nordisk, consultant; Recordati Rate Diseases, consultant; H Lundbeck A/S, consultant. 

All relevant financial relationships have been mitigated. All others in control of content have indicated no relevant financial relationship with an ACCME-defined ineligible company. All clinical content presented will be evidence-based and unbiased.